EUCTR2017-001334-26-ES进行中（未招募）1 期
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY - Long-term Safety Study of AR101 CODIT™
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects must meet all the following criteria to be eligible:
- •1. Prior participation in one of the following Aimmune AR101 clinical studies: ARC002, ARC004, ARC007, ARC010, ARC011, or any future clinical study that identifies ARC008 as a follow-on study option in the protocol
- •2. Written informed consent from the subject or parent/guardian in accordance with local Institutional Review Board (IRB)/Ethics Committee (EC) guidelines
- •3. Written assent from the subject as required by local IRB/EC guidelines
- •4. Use of effective birth control by sexually active females of childbearing potential
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 1060
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 50
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects who meet any of the following criteria are not eligible:
- •1. Did not complete a minimum of 3 months of AR101 Maintenance in the parent study if subject was assigned to AR101 in that study.
- •2. For subjects treated with AR101 in the parent study requiring a food challenge, failure to successfully consume at least the 300 mg single dose (443 mg cumulative) of peanut protein at parent study's exit food challenge
- •3. History of chronic disease (other than asthma, atopic dermatitis, or allergic rhinitis) that is, or is at significant risk of, becoming unstable or requiring a change in chronic therapeutic regimen, including autoimmune diseases and malignancies
- •4. Subjects with a history of alcohol, illicit or recreational drug or prescribed medication abuse
- •5. Developed a clinically significant change in health status during the parent study that, in the opinion of the investigator, would make the subject unsuitable for participation in this study
- •6. Taking a prohibited medication, as listed in Section 5.9.5 of the trial protocol
- •7. Currently participating in any other interventional clinical study other than the Aimmune parent study
- •8. Participation in any peanut immunotherapy clinical study, other than Aimmune-sponsored AR101 studies (including oral, sublingual, or epicutaneous), within 5 years prior to Screening, except for Aimmune Studies ARC002, ARC004, ARC007, ARC010 and ARC011
- •9. Subject is living in the same household or is a dependent of sponsor employees and/or site staff involved in conducting this study, except for subjects originating from Aimmune Studies ARC002, ARC004, ARC007, ARC010 and ARC011
- •10. Except for subjects from ARC002, subjects currently receiving, or having received in the last 5 years, any type of non-peanut allergen immunotherapy (including subcutaneous, sublingual, oral or other)
- •11. Hypersensitivity to epinephrine or hypersensitivity to any of the excipients in the investigational product (IP)
- •12. Pregnant or breastfeeding
- •13. Inability to withhold antihistamines for 5 half-lives prior to initial day of escalation or visits at which a skin prick test (SPT) or open-label food challenge (OLFC) is conducted
- •14. Discontinued early from the parent study for any safety reason (other than a subject from study ARC004 who has experienced a lack of tolerance for a nondaily dosing regimen)
- •15. Any other condition that, in the opinion of the investigator, precludes participation for reasons of safety
- •16. Subjects unable to follow the protocol requirements
研究者
相似试验
进行中（未招募）
1 期
PEANUT ALLERGY STUDYEUCTR2017-001334-26-GBAimmune Therapeutics, Inc.950
进行中（未招募）
1 期
PEANUT ALLERGY STUDYPeanut AllergyEUCTR2017-001334-26-FRAimmune Therapeutics, Inc.1,100
未知
3 期
ong-term Treatment Study of CDP870 without coadministration of MTX in Japanese RA patientsRheumatoid ArthritisJPRN-jRCT2080220676Astellas Pharma Inc.130
未知
3 期
ong-term Treatment Study of CDP870 as Add-on Medication to MTX in Japanese RA patientsRheumatoid ArthritisJPRN-jRCT2080220675Astellas Pharma Inc.222
进行中（未招募）
不适用
A Long-Term, Multicenter, Open-Label Safety Study with Oral 20 or 40 mg/d Doses of KW-6002 (Istradefylline) as Treatment for Parkinson’s Disease in Patients with Motor Response Complications on Levodopa TherapyParkinson's DiseaseEUCTR2004-002844-93-LTKyowa Hakko U.K. Limited1,175